Home > Publications Database > Seizures as an early symptom of autosomal dominant Alzheimer's disease. > print |
001 | 140511 | ||
005 | 20240321220825.0 | ||
024 | 7 | _ | |a 10.1016/j.neurobiolaging.2018.11.022 |2 doi |
024 | 7 | _ | |a pmid:30616208 |2 pmid |
024 | 7 | _ | |a pmc:PMC6572755 |2 pmc |
024 | 7 | _ | |a 0197-4580 |2 ISSN |
024 | 7 | _ | |a 1558-1497 |2 ISSN |
024 | 7 | _ | |a altmetric:52349038 |2 altmetric |
037 | _ | _ | |a DZNE-2020-06833 |
041 | _ | _ | |a English |
082 | _ | _ | |a 610 |
100 | 1 | _ | |a Vöglein, Jonathan |0 P:(DE-2719)2811820 |b 0 |e First author |u dzne |
245 | _ | _ | |a Seizures as an early symptom of autosomal dominant Alzheimer's disease. |
260 | _ | _ | |a Amsterdam [u.a.] |c 2019 |b Elsevier Science |
264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2019-04-01 |
336 | 7 | _ | |a article |2 DRIVER |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1707492936_2407 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
520 | _ | _ | |a Our objective was to assess the reported history of seizures in cognitively asymptomatic mutation carriers for autosomal dominant Alzheimer's disease (ADAD) and the predictive value of seizures for mutation carrier status in cognitively asymptomatic first-degree relatives of ADAD patients. Seizure occurrence in the Dominantly Inherited Alzheimer Network observational study was correlated with mutation carrier status in cognitively asymptomatic subjects. Of 276 cognitively asymptomatic individuals, 11 (4%) had experienced seizures, and nine of these carried an ADAD mutation. Thus, in the Dominantly Inherited Alzheimer Network population, seizure frequency in mutation carriers was significantly higher than in noncarriers (p = 0.04), and the positive predictive value of seizures for the presence of a pathogenic mutation was 81.8%. Among cognitively asymptomatic ADAD family members, the occurrence of seizures increases the a priori risk of 50% mutation-positive status to about 80%. This finding suggests that ADAD mutations increase the risk of seizures. |
536 | _ | _ | |a 344 - Clinical and Health Care Research (POF3-344) |0 G:(DE-HGF)POF3-344 |c POF3-344 |f POF III |x 0 |
536 | _ | _ | |a 342 - Disease Mechanisms and Model Systems (POF3-342) |0 G:(DE-HGF)POF3-342 |c POF3-342 |f POF III |x 1 |
542 | _ | _ | |i 2019-04-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 2 | |a Adult |2 MeSH |
650 | _ | 2 | |a Alzheimer Disease: complications |2 MeSH |
650 | _ | 2 | |a Alzheimer Disease: genetics |2 MeSH |
650 | _ | 2 | |a Female |2 MeSH |
650 | _ | 2 | |a Genes, Dominant: genetics |2 MeSH |
650 | _ | 2 | |a Genetic Association Studies |2 MeSH |
650 | _ | 2 | |a Heterozygote |2 MeSH |
650 | _ | 2 | |a Humans |2 MeSH |
650 | _ | 2 | |a Male |2 MeSH |
650 | _ | 2 | |a Mutation: genetics |2 MeSH |
650 | _ | 2 | |a Observational Studies as Topic |2 MeSH |
650 | _ | 2 | |a Predictive Value of Tests |2 MeSH |
650 | _ | 2 | |a Risk |2 MeSH |
650 | _ | 2 | |a Seizures: etiology |2 MeSH |
650 | _ | 2 | |a Seizures: genetics |2 MeSH |
700 | 1 | _ | |a Noachtar, Soheyl |b 1 |
700 | 1 | _ | |a McDade, Eric |b 2 |
700 | 1 | _ | |a Quaid, Kimberly A |b 3 |
700 | 1 | _ | |a Salloway, Stephen |b 4 |
700 | 1 | _ | |a Ghetti, Bernardino |b 5 |
700 | 1 | _ | |a Noble, James |b 6 |
700 | 1 | _ | |a Berman, Sarah |b 7 |
700 | 1 | _ | |a Chhatwal, Jasmeer |b 8 |
700 | 1 | _ | |a Mori, Hiroshi |b 9 |
700 | 1 | _ | |a Fox, Nick |b 10 |
700 | 1 | _ | |a Allegri, Ricardo |b 11 |
700 | 1 | _ | |a Masters, Colin L |b 12 |
700 | 1 | _ | |a Buckles, Virginia |b 13 |
700 | 1 | _ | |a Ringman, John M |b 14 |
700 | 1 | _ | |a Rossor, Martin |b 15 |
700 | 1 | _ | |a Schofield, Peter R |b 16 |
700 | 1 | _ | |a Sperling, Reisa |b 17 |
700 | 1 | _ | |a Jucker, Mathias |0 P:(DE-2719)2000010 |b 18 |u dzne |
700 | 1 | _ | |a Laske, Christoph |0 P:(DE-2719)2000055 |b 19 |u dzne |
700 | 1 | _ | |a Paumier, Katrina |b 20 |
700 | 1 | _ | |a Morris, John C |b 21 |
700 | 1 | _ | |a Bateman, Randall J |b 22 |
700 | 1 | _ | |a Levin, Johannes |0 P:(DE-2719)2811659 |b 23 |u dzne |
700 | 1 | _ | |a Danek, Adrian |0 P:(DE-2719)2810712 |b 24 |e Last author |u dzne |
700 | 1 | _ | |a Network, Dominantly Inherited Alzheimer |b 25 |
773 | 1 | 8 | |a 10.1016/j.neurobiolaging.2018.11.022 |b : Elsevier BV, 2019-04-01 |p 18-23 |3 journal-article |2 Crossref |t Neurobiology of Aging |v 76 |y 2019 |x 0197-4580 |
773 | _ | _ | |a 10.1016/j.neurobiolaging.2018.11.022 |g Vol. 76, p. 18 - 23 |0 PERI:(DE-600)1498414-3 |q 76<18 - 23 |p 18-23 |t Neurobiology of aging |v 76 |y 2019 |x 0197-4580 |
856 | 7 | _ | |2 Pubmed Central |u http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572755 |
856 | 4 | _ | |u https://pub.dzne.de/record/140511/files/DZNE-2020-06833_Restricted.pdf |
856 | 4 | _ | |u https://pub.dzne.de/record/140511/files/DZNE-2020-06833_Restricted.pdf?subformat=pdfa |x pdfa |
909 | C | O | |p VDB |o oai:pub.dzne.de:140511 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2811820 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 18 |6 P:(DE-2719)2000010 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 19 |6 P:(DE-2719)2000055 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)2811659 |
910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 24 |6 P:(DE-2719)2810712 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
913 | 1 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-342 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Disease Mechanisms and Model Systems |x 1 |
914 | 1 | _ | |y 2019 |
915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-10 |w ger |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEUROBIOL AGING : 2021 |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-10 |
915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-10 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-10 |
915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEUROBIOL AGING : 2021 |d 2022-11-10 |
920 | 1 | _ | |0 I:(DE-2719)1110002 |k AG Höglinger 1 |l Translational Neurodegeneration |x 0 |
920 | 1 | _ | |0 I:(DE-2719)1210001 |k AG Jucker |l Cell Biology of Neurological Diseases |x 1 |
920 | 1 | _ | |0 I:(DE-2719)1111016 |k AG Levin |l Clinical Neurodegeneration |x 2 |
920 | 1 | _ | |0 I:(DE-2719)7000003 |k U Clinical Researchers - München |l U Clinical Researchers - München |x 3 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a I:(DE-2719)1110002 |
980 | _ | _ | |a I:(DE-2719)1210001 |
980 | _ | _ | |a I:(DE-2719)1111016 |
980 | _ | _ | |a I:(DE-2719)7000003 |
980 | _ | _ | |a UNRESTRICTED |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|